Guestrow, Mecklenburg-Vorpommern, Germany, This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor positive breast cancer by using a special test Oncotype DXand whether hormone therapy alone or hormone therapy together with combination chemotherapy is better for women who have an Oncotype DX recurrence score of To determine whether perceived cognitive impairment, fatigue, fear of recurrence, endocrine symptoms, and overall HRQL are similar for ontario registered sex offenders map houston in Lismore receiving hormonal therapy alone in secondary study group 1 as for those in the primary study group arms A vs B.
Actual Primary Completion Date :. Design 1: Lapatinib mg oral daily for a total of 52 weeks. If several lesions are found to be HER2 positive locally, the largest lesion should be considered for central review. For Design 2B: Randomisation must be performed no longer than 8 weeks from definitive surgery.
To determine whether perceived cognitive impairment, fatigue, fear of recurrence, endocrine symptoms, and overall HRQL are similar for patients receiving hormonal therapy alone in secondary study group 1 as for those in the primary study group arms A vs B.
Epub Jun ontario registered sex offenders map houston in Lismore.
The purpose of the analysis is to develop more precise estimates of the relationship between recurrence score and chemotherapy treatment effect, if any, at the upper range of the RS 11 - 25 group. Warning You have reached the maximum number of saved studies New tests may provide information about which patients are more likely to benefit from chemotherapy.
Philadelphia, Pennsylvania, United States,
To determine whether adjuvant hormonal therapy is not inferior to adjuvant chemohormonal in women whose tumors meet established clinical guidelines for adjuvant chemotherapy and fall in the "primary study group" category Oncotype DX Recurrence Score Hamm-Heessen, Nordrhein-Westfalen, Germany, Colorado Springs, Colorado, United States,